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A b s t r a c t
Introduction: The aim of the current study was to evaluate the association 
between lipoprotein(a) [Lp(a)] and major adverse cardiovascular events 
(MACEs) in patients with percutaneous coronary intervention (PCI) treatment.
Material and methods: This was a  retrospective study. The demographics, 
prior medical histories, comorbidities and laboratory parameters were col-
lected from the electronic health record. All participants were followed up 
for 1 year after the indexed PCI. Studied end points were a  composite of 
MACEs including all-cause mortality, non-fatal myocardial infarction (MI), 
non-fatal ischemic stroke, transient ischemic attack and stent restenosis. 
Results: During 1-year follow-up, 87 MACEs occurred. Compared to patients 
who did not have MACEs, patients who had MACEs were older, more likely 
to have higher body mass index, diabetes mellitus and left main lesion, and 
also had higher baseline low density lipoprotein cholesterol (LDL-C) and Lp(a) 
levels. All patients in both groups were prescribed aspirin and clopidogrel at 
discharge. Nearly 97.4% and 95.4% of patients in both groups were treated 
with statins and a  higher proportion of patients in the MACE group were 
treated with ezetimibe (11.5% vs. 3.5%, p < 0.05). In multivariate regression 
analysis, diabetes mellitus, LDL-C, Lp(a) and glomerular filtration rate were 
independent risk factors for MACEs; statin use appeared to be a protective 
factor for MACEs. Patients with increased Lp(a) level had significantly higher 
incidence of MACEs than the normal Lp(a) level group (p = 0.001).
Conclusions: Baseline serum Lp(a) can be used to predict MACEs in patients 
after PCI treatment, which was independent of LDL-C.
Key words: lipoprotein(a), major adverse cardiovascular events, 
percutaneous coronary intervention.
Introduction
Low density lipoprotein cholesterol (LDL-C) is a major risk factor for ath-
erosclerotic cardiovascular diseases (ASCVD) [1–4]. Furthermore, a  sub-
stantial number of clinical studies have demonstrated that lower serum 
level of LDL-C is associated with better cardiovascular prognosis [5–7]. 
Besides LDL-C, in the last two decades, some studies have shown that li-
poprotein(a) [Lp(a)] might be an independent risk factor for ASCVD [8–10]. 
However, some studies suggested that after accounting for the effects of 
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LDL-C, the association between Lp(a) and cardio-
vascular outcome was insignificant [11–14]. 
Structurally [15], Lp(a) comprises two essential 
components, namely LDL-C and apolipoprotein(a) 
[Apo(a)]. Contrary to LDL-C, Lp(a) catabolism is 
less dependent on LDL-C receptor, and prior stud-
ies have shown that statins have a modest effect 
on Lp(a) regulation [15]. Pathophysiologically [16], 
compared to LDL-C, Lp(a) is not only capable of 
promoting atherosclerosis but also capable of 
enhancing thrombus formation through impair-
ing fibrinolysis. The pathophysiological process of 
coronary artery stent restenosis is characterized 
by endothelial dysfunction, smooth muscle cell 
proliferation and fibrin accumulation [17]. There-
fore, with respect to the unique features of Lp(a) 
in terms of pro-atherosclerosis and pro-thrombo-
sis, one may anticipate that increased serum Lp(a) 
level could be associated with higher risk of cardio-
vascular events. However, the data on the associa-
tion between serum Lp(a) level and cardiovascular 
outcomes including coronary artery stent resteno-
sis in Chinese populations are limited [18, 19]. 
Therefore, we conducted a  retrospective co-
hort study to evaluate the association between 
baseline serum Lp(a) level and cardiovascular out-
comes in patients within 1 year after percutane-
ous coronary intervention (PCI) treatment. We be-
lieve that data from our current study will provide 
insights into the function of Lp(a) as regards car-
diovascular outcomes in patients after coronary 
artery stenting. In addition, our current study also 
will provide a foundation for clinical trials aimed 
at reducing cardiovascular events in the future. 
Material and methods
Participants’ enrollment
Our current study was approved by the Clini-
cal Research Ethic Committee of Xiang’an Hospi-
tal of Xiamen University and the First College of 
Clinical Medical Sciences of China Three Gorges 
University. Since this was a retrospective study, no 
informed consent was required from participants. 
The inclusion criteria were as follows: ≥ 18 years 
old, received PCI at our hospital and had follow-up 
at our hospital within the first year after PCI treat-
ment. The exclusion criteria were as follows: had 
documented familial dyslipidemia, and had severe 
complications including hemodynamic instability, 
acute coronary artery stent thrombosis or cor-
onary artery dissection during indexed PCI. The 
study schematic diagram is presented in Figure 1. 
Data collection 
The demographics such as age and gender 
were collected from the electronic health record 
(EHR). Body mass index (BMI) was calculated as 
weight in kilograms divided by height in squared 
meters. Prior documented medical histories and 
comorbidities were collected from the EHR. Lab-
oratory parameters were also collected from the 
EHR. Per hospital protocol, fasting blood samples 
were drawn before the indexed PCI. Serum level 
of Lp(a) was measured with a sandwich enzyme 
linked immune-sorbent assays (ELISA kit, Yaji 
Biosystems, Shanghai, China). All the procedures 
were performed in accordance with the manual 
instructions and were assessed by a SYNCHRON 
LX20 UniCel DxC800 analyzer (Beckman Coulter 
Inc., USA). Baseline serum creatinine level was 
used to calculate the glomerular filtration rate 
(GFR) in accordance with the Modification of Diet 
in Renal Disease (MDRD) formula [20].
Studied end points 
All participants were followed up for 1 year after 
the indexed PCI and parameters of interest were 
collected from the EHR. In specific, studied end 
points of the current study were the composite 
of major adverse cardiovascular events (MACEs) 
including all-cause mortality, non-fatal myocardi-
al infarction (MI), non-fatal ischemic stroke, tran-
sient ischemic attack and stent restenosis. All the 
events were adjudicated by independent cardiol-
ogists. All data extraction was conducted by two 
investigators. 
Statistical analysis 
Continuous data were presented as mean ± 
standard deviation (SD) or median (interquartile 
Figure 1. Study schematic diagram
586 patients who had underwent percutaneous 
coronary intervention during 2016–2017 were screened
34 were excluded: 4 were < 18 years old; 6 had familiar 
dyslipidemia; 16 had hemodynamic instability; 1 had 
acute stent thrombosis; 7 had coronary artery dissection 
during indexed percutaneous coronary intervention 
552 patients were qualified to included criteria
125 patients follow-up less than 1 year at our hospital 
were excluded 
427 patients follow-up at our hospital for at least  
1 year were included into final analysis 
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range, IQR) as appropriate, and were compared 
by Student’s t-test when data were normally dis-
tributed, and otherwise were compared by the 
Wilcoxon rank-sum test. Categorical data were 
presented as number (proportion) and compared 
by the χ2 test or Fisher’s exact test as appropri-
ate. Univariate and multivariate regression anal-
ysis was performed to evaluate the association 
between serum Lp(a) level and MACEs. A  Ka-
plan-Meier survival curve was plotted to evaluate 
the accumulative incidence of MACEs between 
normal and increased serum Lp(a) level groups, 
and the cutoff value was 30 mg/dl in accordance 
with prior reports [11, 15]. All reported p-val-
ues were 2-sided, and a  p-value of < 0.05 was 
considered statistically significant. All statistical 
analyses were conducted with the SPSS statisti-
cal package for Windows version 19.0 (SPSS Inc., 
Chicago, Illinois).
Results
Participants’ enrollment 
Participants’ enrollment was performed from 
January of 2016 to January of 2017. As present-
ed in Figure 1, a total of 586 patients who under-
went PCI in our hospital during this period were 
screened and 34 were excluded in accordance 
with the exclusion criteria. Among the 552 pa-
tients, 427 who were followed up at our hospital 
for at least 1 year after the indexed PCI were re-
cruited into the final analysis.
MACEs during 1-year follow-up
During the first year follow-up, a  total of 87 
(20.4%) MACEs occurred. In specific, 3 (3.4%) pa-
tients died, 19 (21.8%) patients had non-fatal MI, 
22 (26.3%) patients had non-fatal ischemic stroke, 
9 (10.3%) had transient ischemic attack and 34 
(39.1%) had stent restenosis. All the events were 
adjudicated by independent cardiologists. Per 
study protocol, all patients were divided into two 
groups, namely without and with MACEs groups, 
and between-group differences were evaluated. 
Baseline characteristics 
As presented in Table I, compared to patients 
who did not have MACEs, patients who had MACEs 
during the follow-up were older (57.9 ±12.2 years 
vs. 52.2 ±13.8 years), and were more likely to 
have higher BMI (25.1 ±5.0 kg/m2 vs. 23.4 ±4.2 
kg/m2), diabetes mellitus (37.9% vs. 32.1%) and 
left main lesion (20.7% vs. 14.1%), and also had 
higher baseline LDL-C (3.5 ±0.6 mmol/l vs. 3.0 ±0.8 
mmol/l) and Lp(a) (55.6 ±14.3 mg/dl vs. 29.8 ±7.6 
mg/dl) levels (p < 0.05 for all comparisons). No 
other significant differences were observed. 
Medications used at discharge
As presented in Table II, all patients in both groups 
were prescribed aspirin and clopidogrel at discharge. 
Table I. Baseline characteristic comparisons 
Variables Without 
MACEs
(n = 340)
MACEs
(n = 87)
Male, n (%) 196 (57.6) 48 (55.2)
Age [years] 52.2 ±13.8 57.9 ±12.2*
Current smoker, n (%) 86 (25.3) 25 (28.7)
Body mass index [kg/m2] 23.4 ±4.2 25.1 ±5.0*
Hypertension, n (%) 144 (42.4) 37 (44.8)
Diabetes mellitus, n (%) 109 (32.1) 33 (37.9)*
Dyslipidemia, n (%) 128 (37.6) 35 (40.2)
Atrial fibrillation, n (%) 16 (4.7) 6 (6.9)
Ischemic stroke, n (%) 40 (11.8) 10 (11.5)
Peripheral vascular 
disease, n (%)
28 (8.2) 8 (9.2)
Chronic heart failure, n (%) 22 (6.5) 7 (8.0)
Systolic blood pressure 
[mm Hg]
129 ±18 131 ±20
Diastolic blood pressure 
[mm Hg]
70 ±16 72 ±19
Heart rate [beats/min] 78 ±16 79 ±14
Total cholesterol [mmol/l] 4.5 ±0.7 4.8 ±0.7
Triglyceride [mmol/l] 1.6 ±0.6 1.7 ±0.8
LDL-C [mmol/l] 3.0 ±0.8 3.5 ±0.6*
HDL-C [mmol/l] 1.1 ±0.4 1.0 ±0.3
Lipoprotein(a) [mg/dl]) 29.8 ±7.6 55.6 ±14.3*
Creatinine [μmol/l] 70.4 ±15.2 71.9 ±13.8
Glomerular filtration rate 
[ml/min/1.73 m2]
81.9 ±10.4 78.3 ±9.5
Fasting plasma glucose 
[mmol/l]
5.8 ±0.7 5.7 ±0.9
Hemoglobin A1c (%) 6.3 ±0.6 6.4 ±0.5
Left main, n (%) 48 (14.1) 18 (20.7)*
Left anterior descending, 
n (%)
117 (34.4) 32 (36.8)
Left circumflex, n (%) 86 (25.3) 23 (26.4)
Right coronary artery, n (%) 103 (30.3) 28 (32.1)
Number of stents implanted 1.5 ±0.7 1.6 ±0.8
Drug-eluting stents, n (%) 335 (95.5) 82 (94.3)
Left ventricular ejection 
fraction (%)
52.4 ±8.6 50.7 ±7.9
*P < 0.05 versus without MACE group; MACE – major adverse 
cardiovascular events, LDL-C – low-density lipoprotein cholesterol, 
HDL-C – high-density lipoprotein cholesterol.
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Nearly 97.4% and 95.4% of patients in both groups 
were treated with statins and a higher proportion of 
patients in the MACE group were treated with ezeti-
mibe than the group without MACE (11.5% vs. 3.5%, 
p < 0.05). No significant differences in use of other 
medications were observed. 
Independent risk factors for MACEs
Univariate and multivariate regression analy-
sis were performed to evaluate the independent 
risk factors for MACEs. As presented in Table III, 
in the univariate regression analysis, age, current 
smoking, BMI, diabetes mellitus, LDL-C, Lp(a), GFR 
and statin use were all independently associated 
with MACEs. In the multivariate regression anal-
ysis, only diabetes mellitus (hazard ratio (HR) = 
1.12 and 95% confidence interval (CI): 1.04–1.42), 
LDL-C (HR = 1.08 and 95% CI: 1.04–1.32), Lp(a) 
(HR = 1.05 and 95% CI: 1.02–1.24) and GFR 
(HR = 1.22 and 95% CI: 1.12–1.67) were indepen-
dent risk factors for MACEs, while statin use (HR = 
0.97 and 95% CI: 0.92–0.99) appeared to be a pro-
tective factor for MACEs. 
Accumulative incidence of MACEs by 
different Lp(a) level 
Based on prior reports [10, 15], serum level of 
Lp(a) < 30  mg/dl was considered as the normal 
range and accumulative incidence of MACEs was 
compared between normal and increased Lp(a) 
level groups. As presented in Figure 2, patients 
with an increased Lp(a) level had significantly 
higher incidence of MACEs during the first year’s 
follow-up than that in the normal Lp(a) level group 
(p = 0.001). 
Discussion 
Dyslipidemia, characterized by increased se-
rum LDL-C level, is a major risk factor for ASCVD 
[21]. Prior randomized clinical trials have demon-
strated that a  reduced LDL-C level with statins 
is beneficial to prevent cardiovascular events. 
However, some studies have shown that despite 
LDL-C level being within the target range, some 
patients still have recurrent cardiovascular events. 
It is speculated that other cholesterol components 
Table II. Medication use at discharge
Medications Without 
MACEs
(n = 340)
MACEs
(n = 87)
Aspirin, n (%) 340 (100) 87 (100)
Clopidogrel, n (%) 340 (100) 87 (100)
Statins, n (%) 331 (97.4) 83 (95.4)
Ezetimibe, n (%) 12 (3.5) 10 (11.5)*
ACEi/ARB, n (%) 302 (88.8) 76 (87.4)
β-Blocker, n (%) 286 (84.1) 73 (83.9)
Oral anti-coagulation, n (%) 4 (1.2) 2 (2.3)
Calcium channel blocker, 
n (%)
83 (24.4) 20 (23.0)
Diuretic, n (%) 20 (5.9) 5 (5.7)
Oral anti-diabetic 
medication, n (%)
65 (19.1) 18 (20.7)
Insulin, n (%) 33 (9.7) 10 (11.5)
*P < 0.05 versus without MACE group; MACE – major adverse 
cardiovascular events, ACEi/ARB – angiotensin converting enzyme 
inhibitor/angiotensin receptor blocker.
Table III. Independent risk factors for MACEs
Variables Univariate
HR (95% CI)
Multivariate 
HR (95% CI)
Age [years] 1.20 (1.09–1.57) 1.08 (0.96–1.15)
Male gender (vs. No) 1.04 (0.96–1.12) NS
Current smoking (vs. No) 1.15 (1.04–1.32) 1.02 (0.92–1.23)
Body mass index [kg/m2] 1.20 (1.09–1.38) 1.04 (0.94–1.17)
Hypertension (vs. No) 1.11 (0.92–1.25) NS
Diabetes mellitus (vs. No) 1.34 (1.16–1.86) 1.12 (1.04–1.42)
Chronic heart failure (vs. No) 1.05 (0.95–1.19) NS
LDL-C [mmol/l] 1.28 (1.14–1.61) 1.08 (1.04–1.32)
Lipoprotein(a) [mg/dl] 1.24 (1.11–1.53) 1.05 (1.02–1.24)
Left main (vs. No) 1.09 (0.90–1.45) NS
Left ventricular ejection fraction (%) 1.15 (0.97–1.06) NS
Glomerular filtration rate [ml/min/1.73 m2] 1.40 (1.28–1.94) 1.22 (1.12–1.67)
Statins (vs. No) 0.92 (0.89–0.97) 0.97 (0.92–0.99)
Ezetimibe (vs. No) 0.97 (0.90–1.03) NS
MACE – major adverse cardiovascular events, LDL-C – low-density lipoprotein cholesterol, HR – hazard ratio, CI – confidence interval, 
NS – non-significant.
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such as Lp(a) may be associated with residual car-
diovascular risk [22]. However, prior findings are 
conflicting and the data on the Chinese popula-
tions are limited. Our current study shows that in 
the Chinese patients after PCI treatment, indepen-
dent of LDL-C, baseline serum Lp(a) level is useful 
to predict 1-year cardiovascular outcomes and in-
creased serum Lp(a) level portends a higher MACE 
rate than among those with a normal Lp(a) level. 
Of note, a substantial number of patients after 
PCI treatment still experience recurrent cardiovas-
cular events despite serum LDL-C level being with-
in the target range. The underlying mechanisms 
are multifactorial. Prior studies have shown that 
increased Lp(a) level might contribute to the re-
sidual cardiovascular risk. Indeed, experimental 
studies suggested that Lp(a) induced endothelial 
dysfunction, inflammatory reaction and oxida-
tive stress, which in turn led to atherosclerotic 
initiation and development. Furthermore, some 
clinical studies, but not all, have also shown that 
increased Lp(a) level was associated with higher 
cardiovascular risk. Consistent with prior reports, 
our current study also showed that among pa-
tients after PCI treatment, those who had MACEs 
during follow-up had higher baseline serum LDL-C 
and Lp(a) levels. After adjusting for potential con-
founding factors including LDL-C, Lp(a) remained 
independently associated with MACEs, indicat-
ing that Lp(a) was useful to predict MACEs in the 
Chinese patients after PCI treatment. However, 
since our study was a retrospective study, a caus-
al relationship could not be confirmed and future 
studies are warranted to corroborate our current 
findings. 
Interestingly and importantly, our current study 
showed that the percentage of stent restenosis 
was highest compared to other cardiovascular 
events including all-cause mortality, non-fatal MI, 
non-fatal ischemic stroke and transient ischemic 
attack. Since all participants were followed up at 
our hospital and all participants were compliant 
with dual antiplatelet therapy during the first year 
of follow-up after PCI treatment, we considered 
that the higher stent restenosis risk might not be 
attributable to noncompliance with dual antiplate-
let treatment. In contrast, it might be associated 
with higher serum Lp(a) level. Indeed, authors 
[23, 24] reported that in Chinese patients after PCI 
treatment, baseline increased LDL-C and Lp(a) por-
tended a higher risk of revascularization. Consis-
tent with their study, our current study also found 
that those with increased Lp(a) level had higher 
stent restenosis risk. However, in the prior study, 
after adjusting for baseline LDL-C level, the asso-
ciation between Lp(a) and risk of coronary revas-
cularization was insignificant. In our current study, 
we found that even after adjusting for potential 
covariates including LDL-C, increased serum Lp(a) 
level at baseline remained significantly associated 
with stent restenosis, with a hazard ratio of 1.16 
(95% CI: 1.04–1.25, p = 0.013). Unfortunately, al-
though our study and other studies have shown 
the association between Lp(a) and cardiovascular 
events including stent restenosis, no effective and 
efficient approach could be used to reduce Lp(a) 
level up till now. 
With respect to our preliminary findings, future 
directions should be focused on corroborating 
our findings from the national level of China as 
well as in other population groups. Basic research 
should be conducted to evaluate the underlying 
mechanisms. In addition, future randomized, 
prospective, large-scale trials are necessary to 
demonstrate whether reducing the Lp(a) level can 
prevent cardiovascular events in patients with an 
achieved LDL-C target after treatment [23, 24].
Some limitations of our current study should 
be mentioned: first of all, this was a  retrospec-
tive study which was subjected to the limitation 
of temporal relationship in terms of the associa-
tion between exposure and outcomes; second, the 
observational design could not allow us to infer 
a causal relationship; third, although we adjusted 
for potential confounding factors, unmeasured and 
undetected confounding factors still existed which 
could have impacted the results; fourth, our cur-
rent study concerned a retrospective cohort and no 
LDL-C was obtained after finishing follow-up. How-
ever, our current study was focused on the baseline 
LDL-C and Lp(a) levels in relation to cardiovascular 
outcomes. In addition, in the regression analysis 
model, we adjusted for baseline LDL-C level. In the 
future prospective cohort study, it is necessary to 
evaluate LDL-C change during follow-up; last but 
not the least, our current study was conducted in 
a Chinese population and therefore future studies 
performed in other racial/ethnic populations are 
warranted to corroborate our findings. 
In conclusion, our current study shows that 
in Chinese patients with PCI treatment, baseline 
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serum Lp(a) level can be used to predict MACEs, 
especially stent restenosis, and all these findings 
are independent of baseline LDL-C level. Future 
randomized trials are necessary to demonstrate 
whether reducing the Lp(a) level can further pre-
vent cardiovascular events in patients with an 
achieved LDL-C target. 
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